Enjoy these illustrated stories and learn more about key topics, practices and protocols.
Treat & Extend in ME secondary to CRVO
In the CENTERA study, significant functional and anatomic improvements were achieved by treating macular edema (ME) secondary to central retinal vein occlusion (CRVO) with a treat-and-extend (T&E) dosing regimen. Varun Chaudhary, leading author of the study, explains why T&E might be an ideal approach in these patients.
The management of myopic CNV, explained by Paolo Lanzetta.
Treat & Extend
The T&E dosing regimen, and the advantages of this treatment modality for patients and physicians, explained by Gemmy Cheung.
To switch or not to switch?
An expert guide in how to deal with poor response to anti-VEGF in diabetic macula edema.
Which anti-VEGF treatment regimen?
Intravitreal anti-vascular endothelial growth factor agents, such as aflibercept, ranibizumab, and bevacizumab, have revolutionised the way neovascular retinal diseases are managed. However, there are still questions about the most effective dosing schedule for these medications to help optimise treatment effect and patient experience. Here, Sebastian Wolf highlights the key differences between the most commonly used dosing schedule.
DRCR.net Protocol T study: 1- and 2-year results
Sanjay Sharma gives an overview of both the 1- and 2-year results from the DRCR.net Protocol T study comparing aflibercept, ranibizumab and bevacizumab.
An animated explanation of HFMEA and IVEG narrated by Paolo Lanzetta.